VanEck Associates’s Takeda Pharmaceutical TAK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$20.6M Sell
1,331,432
-840,952
-39% -$13M 0.02% 337
2025
Q1
$32.3M Sell
2,172,384
-38,044
-2% -$566K 0.04% 248
2024
Q4
$29.3M Buy
2,210,428
+35,192
+2% +$466K 0.04% 255
2024
Q3
$30.1M Buy
2,175,236
+134,407
+7% +$1.86M 0.04% 243
2024
Q2
$26.4M Buy
2,040,829
+356,069
+21% +$4.61M 0.04% 239
2024
Q1
$23.4M Buy
1,684,760
+360,844
+27% +$5.01M 0.04% 242
2023
Q4
$18.9M Buy
1,323,916
+45,616
+4% +$651K 0.03% 259
2023
Q3
$19.8M Buy
1,278,300
+226,754
+22% +$3.51M 0.04% 242
2023
Q2
$16.5M Buy
1,051,546
+34,691
+3% +$545K 0.04% 275
2023
Q1
$16.8M Sell
1,016,855
-768,351
-43% -$12.7M 0.04% 266
2022
Q4
$27.8M Sell
1,785,206
-76,816
-4% -$1.2M 0.07% 204
2022
Q3
$24.2M Sell
1,862,022
-127,750
-6% -$1.66M 0.07% 200
2022
Q2
$27.9M Buy
1,989,772
+862,502
+77% +$12.1M 0.07% 209
2022
Q1
$16.1M Sell
1,127,270
-26,806
-2% -$384K 0.03% 287
2021
Q4
$15.7M Buy
1,154,076
+281,425
+32% +$3.84M 0.04% 289
2021
Q3
$14.3M Buy
872,651
+249,686
+40% +$4.09M 0.04% 296
2021
Q2
$10.5M Buy
622,965
+60,231
+11% +$1.01M 0.02% 342
2021
Q1
$10.3M Sell
562,734
-44,044
-7% -$804K 0.03% 338
2020
Q4
$11M Buy
606,778
+18,080
+3% +$329K 0.03% 289
2020
Q3
$10.5M Buy
588,698
+27,839
+5% +$497K 0.03% 255
2020
Q2
$10.1M Buy
560,859
+72,748
+15% +$1.3M 0.04% 257
2020
Q1
$7.41M Buy
488,111
+44,999
+10% +$683K 0.04% 261
2019
Q4
$8.74M Buy
443,112
+70,140
+19% +$1.38M 0.03% 280
2019
Q3
$6.42M Sell
372,972
-66,367
-15% -$1.14M 0.03% 294
2019
Q2
$7.78M Buy
439,339
+30,751
+8% +$544K 0.04% 262
2019
Q1
$8.32M Buy
+408,588
New +$8.32M 0.04% 244